• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

极光激酶抑制剂骨架和结合模式。

Aurora-A kinase inhibitor scaffolds and binding modes.

机构信息

State Key Laboratory of Chemical Resource Engineering, Department of Pharmaceutical Engineering, PO Box 53, Beijing University of Chemical Technology, 15 BeiSanHuan East Road, Beijing 100029, China.

出版信息

Drug Discov Today. 2011 Mar;16(5-6):260-9. doi: 10.1016/j.drudis.2010.12.003. Epub 2010 Dec 13.

DOI:10.1016/j.drudis.2010.12.003
PMID:21147253
Abstract

Aurora kinases (A-C) belong to the serine/threonine protein kinase family. In recent years, the constitutive or elevated expression of Aurora kinases has been found in cancer cells and oncogene transfected cells. In this review, we summarize the common binding modes of Aurora-A kinase inhibitors, the hot spot residues in the binding sites and the privileged inhibitor structures. Our review of the reported chemical scaffolds of Aurora-A kinase inhibitors and their binding modes could provide a useful framework from which new design strategies for inhibitors might be assessed or developed.

摘要

极光激酶(A-C)属于丝氨酸/苏氨酸蛋白激酶家族。近年来,在癌细胞和癌基因转染细胞中发现极光激酶的组成型或升高表达。在这篇综述中,我们总结了极光 A 激酶抑制剂的常见结合模式、结合位点的热点残基和优势抑制剂结构。我们对报道的极光 A 激酶抑制剂的化学骨架及其结合模式的综述,可以为抑制剂的新设计策略的评估或开发提供一个有用的框架。

相似文献

1
Aurora-A kinase inhibitor scaffolds and binding modes.极光激酶抑制剂骨架和结合模式。
Drug Discov Today. 2011 Mar;16(5-6):260-9. doi: 10.1016/j.drudis.2010.12.003. Epub 2010 Dec 13.
2
Advances in Aurora kinase inhibitor patents.极光激酶抑制剂专利的进展。
Expert Opin Ther Pat. 2009 Mar;19(3):321-56. doi: 10.1517/13543770802646949.
3
Aurora kinases: new targets for cancer therapy.极光激酶:癌症治疗的新靶点。
Clin Cancer Res. 2006 Dec 1;12(23):6869-75. doi: 10.1158/1078-0432.CCR-06-1405.
4
Is there a future for Aurora kinase inhibitors for anticancer therapy?极光激酶抑制剂用于抗癌治疗的前景如何?
Curr Opin Drug Discov Devel. 2009 Jul;12(4):533-42.
5
Clinical experience with aurora kinase inhibitors: a review.极光激酶抑制剂的临床经验:综述
Oncologist. 2009 Aug;14(8):780-93. doi: 10.1634/theoncologist.2009-0019. Epub 2009 Aug 14.
6
Aurora kinase inhibitors.极光激酶抑制剂。
Crit Rev Oncol Hematol. 2010 Feb;73(2):99-110. doi: 10.1016/j.critrevonc.2009.03.009. Epub 2009 Apr 14.
7
Development and biological evaluation of a novel aurora A kinase inhibitor.一种新型极光A激酶抑制剂的研发与生物学评价
Chembiochem. 2009 Feb 13;10(3):464-78. doi: 10.1002/cbic.200800600.
8
Aurora kinases as targets for cancer therapy.极光激酶作为癌症治疗的靶点。
Cancer Treat Rev. 2008 Apr;34(2):175-82. doi: 10.1016/j.ctrv.2007.09.005. Epub 2007 Nov 19.
9
Aurora kinases as anticancer drug targets.极光激酶作为抗癌药物靶点。
Clin Cancer Res. 2008 Mar 15;14(6):1639-48. doi: 10.1158/1078-0432.CCR-07-2179.
10
Identification, SAR studies, and X-ray co-crystallographic analysis of a novel furanopyrimidine aurora kinase A inhibitor.新型呋喃嘧啶类 Aurora 激酶 A 抑制剂的鉴定、SAR 研究及 X 射线共晶结构分析。
ChemMedChem. 2010 Feb 1;5(2):255-67. doi: 10.1002/cmdc.200900339.

引用本文的文献

1
Binding selectivity analysis of AURKs inhibitors through molecular dynamics simulation studies.通过分子动力学模拟研究 AURKs 抑制剂的结合选择性分析。
PLoS One. 2023 Dec 19;18(12):e0295741. doi: 10.1371/journal.pone.0295741. eCollection 2023.
2
Computational and Biophysical Characterization of Heterocyclic Derivatives of Anthraquinone against Human Aurora Kinase A.蒽醌杂环衍生物对人极光激酶A的计算和生物物理特性研究
ACS Omega. 2022 Oct 27;7(44):39603-39618. doi: 10.1021/acsomega.2c00740. eCollection 2022 Nov 8.
3
Design, Synthesis, and Biochemical Evaluation of New Triazole Derivatives as Aurora-A Kinase Inhibitors.
新型三唑衍生物的设计、合成及作为 Aurora-A 激酶抑制剂的生化评价。
Molecules. 2021 Sep 18;26(18):5678. doi: 10.3390/molecules26185678.
4
Synthetic Strategies of Pyrimidine-Based Scaffolds as Aurora Kinase and Polo-like Kinase Inhibitors.嘧啶类骨架作为 Aurora 激酶和 Polo 样激酶抑制剂的合成策略。
Molecules. 2021 Aug 26;26(17):5170. doi: 10.3390/molecules26175170.
5
Exploring the Inhibitory Mechanism of Approved Selective Norepinephrine Reuptake Inhibitors and Reboxetine Enantiomers by Molecular Dynamics Study.通过分子动力学研究探索已批准的选择性去甲肾上腺素再摄取抑制剂和瑞波西汀对映异构体的抑制机制。
Sci Rep. 2016 May 27;6:26883. doi: 10.1038/srep26883.
6
Benzo[e]pyrimido[5,4-b][1,4]diazepin-6(11H)-one derivatives as Aurora A kinase inhibitors: LQTA-QSAR analysis and detailed systematic validation of the developed model.作为极光激酶A抑制剂的苯并[e]嘧啶并[5,4-b][1,4]二氮杂卓-6(11H)-酮衍生物:LQTA-QSAR分析及所开发模型的详细系统验证
Mol Divers. 2015 Nov;19(4):965-74. doi: 10.1007/s11030-015-9618-y. Epub 2015 Jul 17.
7
Pro-apoptotic and pro-autophagic effects of the Aurora kinase A inhibitor alisertib (MLN8237) on human osteosarcoma U-2 OS and MG-63 cells through the activation of mitochondria-mediated pathway and inhibition of p38 MAPK/PI3K/Akt/mTOR signaling pathway.极光激酶A抑制剂阿利西替尼(MLN8237)通过激活线粒体介导的途径和抑制p38丝裂原活化蛋白激酶/磷脂酰肌醇-3-激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白信号通路对人骨肉瘤U-2 OS和MG-63细胞产生促凋亡和促自噬作用。
Drug Des Devel Ther. 2015 Mar 12;9:1555-84. doi: 10.2147/DDDT.S74197. eCollection 2015.
8
Specificity rendering 'hot-spots' for aurora kinase inhibitor design: the role of non-covalent interactions and conformational transitions.用于极光激酶抑制剂设计的特异性呈现“热点”:非共价相互作用和构象转变的作用
PLoS One. 2014 Dec 8;9(12):e113773. doi: 10.1371/journal.pone.0113773. eCollection 2014.
9
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.2011 年国际许旺细胞瘤研讨会最新进展:从遗传学角度到诊断标准。
Am J Med Genet A. 2013 Mar;161A(3):405-16. doi: 10.1002/ajmg.a.35760. Epub 2013 Feb 7.
10
Integrity of p53 associated pathways determines induction of apoptosis of tumor cells resistant to Aurora-A kinase inhibitors.p53 相关途径的完整性决定了对 Aurora-A 激酶抑制剂耐药的肿瘤细胞凋亡的诱导。
PLoS One. 2013;8(1):e55457. doi: 10.1371/journal.pone.0055457. Epub 2013 Jan 31.